Navigation Links
Sorafenib significantly improves the length of time before breast cancer worsens
Date:9/23/2009

Berlin, Germany: One of the first of a series of trials to investigate the use of sorafenib a targeted anti-cancer drug for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

Principal investigator of the study, Professor Jos Baselga told Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin today (Wednesday 23 September): "This is the first, large, randomised study that demonstrates significant clinical activity of sorafenib in breast cancer when given in combination with chemotherapy. Our results showed that patients who received sorafenib plus capecitabine had a 74% percent improvement in the time they lived without their disease worsening compared to those who received the chemotherapy alone. This is a very positive study and the magnitude of the benefit is such that it suggests that this agent will be an important addition to our therapeutic armoury in breast cancer."

Sorafenib (Nexavar) is a potent multi-kinase inhibitor, which works by interfering with the growth of cancer cells and slowing the growth of new blood vessels within the tumour. Until now, it has only been used in the treatment of kidney and liver cancer.

Prof Baselga, who is head of the oncology department at Vall d'Hebron University Hospital (Barcelona, Spain), president of ESMO (European Society for Medical Oncology) and a member of the ECCO (European CanCer Organisation) executive committee, and his colleagues in Spain, France and Brazil enrolled 229 patients with locally advanced or metastatic breast cancer in the double-blind, randomised phase II clinical trial between June 2007 and December 2008. They randomised the patients to receive capecitabine (1000 mg/m2 pill taken twice daily for 14 of every 21 days) and a placebo (114 women), or capecitabine and sorafenib (400 mg pill taken twice daily continuously) for 115 women.

The very first results from the trial only became available in time for the ECCO 15 ESMO 34 congress, and they show that the average progression free survival (the time that elapses without the cancer getting worse) was 6.4 months for women on capecitabine and sorafenib compared to 4.1 months for women taking the placebo. It is too early for data on overall survival to be available. The only death that occurred was in the placebo arm of the trial, attributed to the effect of capecitabine. The number of patients discontinuing treatment due to adverse side-effects was nine (8%) in the placebo arm and 15 (13.4%) in the sorafenib arm of the trial.

Prof Baselga said: "The regimen was tolerable and the side-effects were mostly manageable. No new or unexpected side effects were observed with this combination. The fact that this treatment could be taken orally may represent a unique and convenient treatment option for patients with breast cancer.

"This trial is an example of good academia and industry partnership. It was designed and conducted by the Spanish breast cooperative group SOLTI with the participation also of Brazilian and French groups. The trial was fully supported by Onyx and Bayer. Based on the encouraging data from this trial so far, Onyx and Bayer are evaluating various strategies for sorafenib in breast cancer.

"This trial is the first of a series of randomised phase II studies with sorafenib that are currently underway in breast cancer. Based on our results, we believe that the drug shows considerable promise for the treatment of the disease."


'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Drug Sorafenib Improves Kidney Cancer Outcomes
2. Sorafenib Shows Promise for Heart-Lung Disease
3. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
4. Sorafenib Slows Growth of Some Leukemias
5. Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men
6. Phoenix Children's Hospital Significantly Reduces Costs with Orion Health™ Technology
7. Radiologists find a technique to significantly reduce patient radiation dose during CT angiography
8. New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated
9. African Americans at Significantly Higher Risk of DVT or Blood Clots
10. Significantly Higher Percentage of Hetastarch Recipients Underwent a Surgical Procedure Than Those Receiving Albumin/Plasma Protein Fraction
11. New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... , ... Kevin Harrington, one of the original Sharks from hit reality series Shark Tank, and ... campaign with My Real Earth. , Most people put their healthcare above their skincare, but ... what we put in our bodies. After all, the skin is the largest organ which ...
(Date:7/28/2017)... ... ... For over 20 years Sealy Baby has been creating crib mattresses that ... pride in using some of nature’s best materials while integrating today’s latest comfort technologies ... mattresses and crib bedding for infants and toddlers. We are thrilled ...
(Date:7/27/2017)... ... July 27, 2017 , ... Conventus, New Jersey’s ... physicians, has launched a new educational series of webinars and podcasts to guide ... prescribing of pain medication. The first two episodes of the series, entitled “Pain ...
(Date:7/27/2017)... ... July 27, 2017 , ... Patients with ... in a single office visit from Dr. Alejandro Kovacs. Dr. Kovacs is a ... East Texas patients, including Teeth-in-a-Day® dental implants in Longview, TX. ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... Verification to State Medicaid programs, Managed Care Organizations and Home Care Agencies, has ... The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies and multiple ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology: